ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 716,07
0,08%
Dow Jones
43 487,83
0,78%
DAX
20 911,95
0,07%
Brent Oil
79,60
-0,77%
Bitcoin
108 366,18
5,09%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Replimune Group Inc (REPL)

  7. Replimune Group Inc (REPL) Actualités

REPL

Replimune (REPL)

Replimune Group Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:REPL
DateHeureSourceTitreSymboleSociété
17/01/202523h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
10/01/202522h01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
08/01/202514h00GlobeNewswire Inc.Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical TrialsNASDAQ:REPLReplimune Group Inc
23/12/202414h00GlobeNewswire Inc.Replimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:REPLReplimune Group Inc
19/12/202403h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
16/12/202422h48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REPLReplimune Group Inc
04/12/202414h30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:REPLReplimune Group Inc
27/11/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
26/11/202423h27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:REPLReplimune Group Inc
26/11/202405h55GlobeNewswire Inc.Replimune Announces Pricing of Upsized Public OfferingNASDAQ:REPLReplimune Group Inc
25/11/202413h09GlobeNewswire Inc.Replimune Announces Proposed Public OfferingNASDAQ:REPLReplimune Group Inc
21/11/202422h05GlobeNewswire Inc.Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval PathwayNASDAQ:REPLReplimune Group Inc
14/11/202413h00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:REPLReplimune Group Inc
12/11/202414h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REPLReplimune Group Inc
12/11/202414h00GlobeNewswire Inc.Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateNASDAQ:REPLReplimune Group Inc
09/11/202419h00GlobeNewswire Inc.Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)NASDAQ:REPLReplimune Group Inc
30/10/202414h15GlobeNewswire Inc.Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:REPLReplimune Group Inc
09/10/202422h01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
01/10/202414h00GlobeNewswire Inc.Replimune to Present at Two Upcoming Investor ConferencesNASDAQ:REPLReplimune Group Inc
15/09/202415h45GlobeNewswire Inc.Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:REPLReplimune Group Inc
09/09/202414h00GlobeNewswire Inc.Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024NASDAQ:REPLReplimune Group Inc
05/09/202414h00GlobeNewswire Inc.Stockholders Vote to Elect Madhavan Balachandran to Board of DirectorsNASDAQ:REPLReplimune Group Inc
22/08/202414h00GlobeNewswire Inc.Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:REPLReplimune Group Inc
15/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:REPLReplimune Group Inc
13/08/202414h00GlobeNewswire Inc.Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced MelanomaNASDAQ:REPLReplimune Group Inc
08/08/202414h45Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:REPLReplimune Group Inc
08/08/202414h00GlobeNewswire Inc.Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate UpdateNASDAQ:REPLReplimune Group Inc
19/07/202422h16Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:REPLReplimune Group Inc
19/07/202422h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:REPLReplimune Group Inc
19/07/202422h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:REPLReplimune Group Inc
 Showing the most relevant articles for your search:NASDAQ:REPL

Dernières Valeurs Consultées

EU
ACA
Credit Agricole
EU
CS
Axa
EU
ML
Michelin
COIN
XRPUSD
Ripple
EU
GLE
Societe Generale
NYSE
NKE
Nike
EU
CAP
Capgemini
NASDAQ
AMZN
Amazon.com
NYSE
JPM
JP Morgan Chase
EU
EN
Bouygues
NYSE
DIS
Walt Disney
COIN
AVAXUSD
Avalanche
COIN
ADAUSD
Cardano
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés